The Associate Director, Clinical Imaging will own the strategy and execution of sophisticated early and late phase oncology imaging in clinical trials where imaging plays a meaningful role.
Imaging includes all modalities with a special focus on CT and PET. In this role, you will lead the development of imaging biomarkers, drive the scientific imaging aspects and tumor response assessment of oncology clinical studies.
We assume you will be an imaging scientific leader and a member of cross-functional program teams including Regeneron clinical and preclinical colleagues as well as external academic and industry partners.
We believe this opportunity provide excellent opportunities to develop innovative imaging biomarkers in support of clinical development and to contribute to bringing more treatment options to patients.
A Typical Day May Include :
Work closely with imaging, therapeutic area and development leads to formulate appropriate imaging biomarker strategies to advise and advance the Regeneron clinical pipeline.
Lead, design and implement multi-modality imaging measures as endpoints for oncology therapeutic clinical studies.
Collaborate closely with Regeneron clinical teams as imaging subject matter expert to ensure optimal design and execution of imaging strategy including development of protocols, imaging manuals, imaging charters and statistical analysis plan.
Work closely with Clinical Imaging Operations and imaging CROs to ensure the flawless conduct and data integrity of study’s imaging components and endpoints.
Serve as Study Director for clinical trials focused on qualification and utilization of novel imaging biomarkers.
Lead the interaction with regulatory agencies and site ethic committees for approval of clinical imaging biomarker development studies.
This Role May Be For You :
You used the application of PET imaging as a quantitative endpoint in clinical and preclinical studies within Oncology
You implemented central efficacy assessment using tumor response criteria such as RECIST 1.1, PCWG3, Lugano and IMWG in oncology clinical trials.
You can clearly and effectively communicate across different modalities and settings
To be considered for this opportunity, you are expected to have completed a PhD program a minimum of 7+ years of clinical imaging experience within oncology drug development.
Experience with clinical PET tracer development is helpful. We also are looking for you to have successful engagements with regulatory professionals.